Table 1.
Baseline characteristics of 258 patients undergoing distal pancreatectomy in the intention-to-treat population.
| MIDP group (n = 131) | ODP group (n = 127) | |
|---|---|---|
| Age—yr. | 69.2 (±8.4) | 68.5 (±9.0) |
| Sex | ||
| Male | 63 (48.1) | 68 (53.5) |
| Female | 68 (51.9) | 59 (46.5) |
| BMI—kg/m2 | 25.2 (22.6–27.9) | 25.8 (23.0–28.7) |
| ASA classification | ||
| I | 13 (9.9) | 6 (4.7) |
| II | 74 (56.5) | 63 (49.6) |
| III | 44 (33.6) | 58 (45.7) |
| Prior abdominal surgery | 89 (67.9) | 77 (60.6) |
| Tumor location | ||
| Pancreatic body | 56 (42.7) | 54 (42.5) |
| Pancreatic tail | 56 (42.7) | 49 (38.6) |
| Body–tail junction | 19 (14.6) | 24 (18.9) |
| Tumor size—mm | 27.0 (20.0–36.0) | 26.5 (20.0–40.0) |
| Splenic vessel involvement on imaging | ||
| Vein involvement | 24 (18.3) | 20 (15.7) |
| Artery involvement | 12 (9.2) | 6 (4.7) |
| Both involved | 36 (27.5) | 38 (30.0) |
| Multivisceral involvement on imaging | 9 (6.9) | 12 (9.4) |
| Neoadjuvant treatment | 23 (17.6) | 28 (22.0) |
| Chemotherapy | 19 (14.5) | 22 (17.3) |
| Radiotherapy | 0 (0.0) | 1 (0.8) |
| Chemoradiation | 4 (3.1) | 5 (3.9) |
| Tumor markers at baseline | ||
| CEA—ng/mL | 2.8 (2.0–6.7) | 2.9 (1.9–6.5) |
| CA 19–9—u/mL | 50.0 (14.0–170.0) | 47.3 (10.8–287.8) |
| Resection performed | 117 (89.3) | 114 (89.8) |
| Received distal pancreatectomy | 116 (88.5) | 112 (88.2) |
| Received pancreatoduodenectomy | 1 (0.8) | 1 (0.8) |
| Received enucleation | 0 (0.0) | 1 (0.8) |
| Received assigned procedure for pancreatic cancer | 94 (71.8) | 100 (78.7) |
Categorical data are reported in numbers and frequencies.
Normally distributed continuous data are reported in mean (SD).
Non-normally distributed continuous data are reported in median (IQR).
MIDP, Minimally invasive distal pancreatectomy; ODP, Open distal pancreatectomy; SD, Standard deviation; IQR, Interquartile range; BMI Body mass index; ASA, American Society of Anesthesiologists; CEA, Carcinoembryonic antigen; CA, Carbohydrate antigen; mL, Millilitre.